Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
SEC, Cassava and Alzheimer's
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.
SEC brings securities fraud charges against Cassava Sciences
The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug
SEC charges Cassava over 'misleading' Alzheimer's claims
The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former head of neuroscience Dr Lindsay Burns of misleading investors by announcing that the company’s small-molecule therapeutic simufilam significantly improved patient cognition in the phase 2b study.
bovnews
1d
How Does Cassava Sciences Inc (SAVA) Stack Up Against Its Industry Peers?
On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $28.49 which represents a decrease of $-3.38 or -10.61% from the prior close of $31.87. The stock opened at $28.08 and ...
FierceBiotech
4d
Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
6d
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
4d
Cassava Sciences Unusual Options Activity
Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...
4d
on MSN
Why Cassava Sciences Stock Dived by Almost 11% Today
Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the ...
13d
on MSN
Cassava Sciences inks consulting pact with ex-CEO Remi Barbier
Cassava Sciences (SAVA) stock gains as company strikes consulting agreement with former CEO Remi Barbier. Read more here.
5d
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
U.S. Securities and Exchange Commission
Alzheimer's disease
Southeastern Conference
Simufilam
Feedback